Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
Mnuchin tells CNBC he's confident President Trump and China's Xi Jinping can make progress in stalled trade talks.World Economyread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
The Supreme Court refused to overturn a precedent that strengthened the power of government regulators in a closely watched case that could have had broad ramifications for...Politicsread more
The president raised $6 million alone at a fundraiser he attended at the Trump International Hotel on Tuesday in Washington.Politicsread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
The red-hot gold trade is cooling off on Wednesday, and Mark Newton of Newton Advisors says the charts point to further weakness to come.Trading Nationread more
The stock market is shrinking for several key reasons, but there's a way for investors to maneuver it, says Citi Research strategist Robert Buckland.Trading Nationread more
Johnson & Johnson delivered quarterly earnings that topped analysts' expectations on Tuesday, but revenue was light as the impact of a strong dollar more than offset higher sales of its mainstay older drugs.
Shares of J&J edged lower in premarket trading following the announcement. (Get the latest quote here.)
The diversified health care giant posted third-quarter adjusted earnings of $1.49 per share, down from $1.50 a share in the year-earlier period.
Net profit fell to $3.36 billion, or $1.20 per share, from $4.75 billion, or $1.66 per share, a year earlier.
Revenue fell to $17.1 billion from $18.47 billion a year ago.
Analysts expected the company to post earnings per share of $1.45 on revenue of $17.45 billion, according to a Thomson Reuters consensus estimate.
J&J also forecast full-year adjusted earnings of $6.15 a share to $6.20 a share.
Earlier Tuesday, the drugmaker said it would buy back up to $10 billion of common stock.
The company said on Tuesday it had about 2.77 billion shares of common stock outstanding as of Sept. 27.
On Friday, J&J said it has begun clinical trials for an Ebola vaccine in Sierra Leone as part of a new study being conducted in the nation's Kambia district, the site of some of the most recent cases.
J&J's stock has lagged in the last year when compared to its rival Pfizer, having fallen more than 5 percent in that time, while Pfizer shares have risen more than 13 percent, according to FactSet data.
—Reuters contributed to this report.